Price
$52.92-8.66%Social Signal Score
Analyst Ratings
14 analystsRevenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- David L. Hallal
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 289
- Beta
- 0.68
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- 7.16
Financials
Revenue
$0.00-100.0%Net Income
$-109.90MEBITDA
$-105.08MFree Cash Flow
$-69.64MEPS (diluted)
$-0.84Shares Outstanding (diluted)
130.61M+629.5%Operating Expenses
$108.90MCash & Debt
$492.09MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-377.94M | $-3.29 |
| 2024 | $0.00 | $-246.29M | $-2.47 |
| 2023 | $0.00 | $-165.79M | $-1.99 |
| 2022 | $33.19M | $-134.50M | $-2.21 |
| 2021 | $18.82M | $-131.80M | $-3.59 |
| 2020 | $15.40M | $-86.48M | $-2.77 |
| 2019 | $20.49M | $-51.00M | $-1.80 |
| 2018 | $0.00 | $-49.33M | $-3.15 |
| 2017 | $0.00 | $-25.00M | $-1.40 |
| 2016 | $379.0K | $-16.21M | $-0.91 |
Valuation
SRRKhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
72+43.33%Social Signal Score
Mentions (13)
- News (RSS)seekingalpha·20d ago·Negative
Scholar Rock downgraded at Barclays despite FDA approval of SMA therapy
View source ↗ - Newsseekingalpha.com·20d ago·Neutral
…sions Now In Play Scholar Rock Holding Corporation maintains a "Strong Buy" rating following FDA approval of ISEMBYLD [apitegromab] for SMA in patients ≥2 years old. SRRK targets a $2B+ market opportunity in SMA, with expansion potential into younger populations, subcutaneous formulations, and new indications like FSHD. Regulatory catalysts include planned MAA resubmission in Europe and anticipated JNDA filing in Japan by year-end 2026, leveraging a validated manufacturing facility.
View source ↗ - News (RSS)seekingalpha·21d ago·Positive
Scholar Rock Holding Corporation (SRRK) Discusses FDA Approval and Clinical Impact of ISEMBYLD in SMA Treatment Transcript
View source ↗ - Newsseekingalpha.com·21d ago·Positive
Scholar Rock Holding Corporation (SRRK) Discusses FDA Approval and Clinical Impact of ISEMBYLD in SMA Treatment Transcript Scholar Rock Holding Corporation (SRRK) Discusses FDA Approval and Clinical Impact of ISEMBYLD in SMA Treatment Transcript
View source ↗ - News (RSS)zerohedge·21d ago·Neutral
…dvanced breast cancer. Rum Group (RUM) rallies 11% after the Information reported that Anthropic has struck a $13.7 billion compute pact with the firm. Scholar Rock (SRRK) rises 6% after the drug developer said the US FDA has approved its muscle-targeted therapy for spinal muscular atrophy. Analysts are positive about the approval, with many raising their price targets ahead of the drug launch. In other corporate news, Anthropic was said to pick Nasdaq for a potential listing. It also told inves…
View source ↗ - Newsbenzinga.com·22d ago·Neutral
Why Scholar Rock Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket Shares of Scholar Rock Holding Corp (NASDAQ:SRRK) rose sharply in pre-market trading after the company announced the FDA approval of ISEMBYLD (apitegromab-mstn), the first and only muscle-targeted treatment for children and adults with Spinal Muscular Atrophy (SMA).
View source ↗ - News (RSS)seekingalpha·22d ago·Neutral
Scholar Rock jumps 12% after FDA approves isembyld for spinal muscular atrophy
View source ↗ - Newsbusinesswire.com·24d ago·Neutral
…tn), the First and Only Muscle-Targeted Treatment for Children and Adults with Spinal Muscular Atrophy (SMA) CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to improving the lives of patients with rare, severe, and debilitating neuromuscular diseases by applying its leading platform in myostatin biology, today announced that the FDA has approved ISEMBYLD (apitegromab-mstn) for the treatment of spinal muscular atrophy (SMA) in adults an…
View source ↗ - Newsreuters.com·24d ago·Negative
US FDA approves Scholar Rock's muscle weakness drug The U.S. Food and Drug Administration on Friday approved Scholar Rock's therapy to treat a rare genetic condition that causes muscle weakness.
View source ↗ - Newsseekingalpha.com·25d ago·Positive
Scholar Rock Holding Corporation (SRRK) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript Scholar Rock Holding Corporation (SRRK) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
View source ↗ - Newsmarketbeat.com·49d ago·Negative
Scholar Rock Eyes Sept. 30 FDA Decision for SMA Drug Apitegromab Scholar Rock NASDAQ: SRRK CEO David Hallal said the company is preparing for a September 30 FDA decision date for apitegromab, its investigational treatment for spinal muscular atrophy, or SMA, following a resubmitted biologics license application supported by an alternate fill-finish manufacturing facility.
View source ↗ - News (RSS)yahoo·52d ago·Neutral
Is Scholar Rock Holding Corporation (SRRK) Better Positioned than Novo Nordisk A/S (NVO) After Recent Setbacks?
View source ↗ - Newsbusinesswire.com·59d ago·Neutral
Scholar Rock Announces FDA Review of Apitegromab Biologics License Application (BLA) for Spinal Muscular Atrophy (SMA) to Progress with Second Fill-Finish Facility; Approval Decision Anticipated by September 30, 2026 Action Date CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to improving the lives of patients with rare, severe, and debilitating neuromuscular diseases by applying its world-leading platform in myostatin biology, today a
View source ↗
Earnings
Fri, Nov 13(in 5 weeks)
Consensus estimate $-0.86 per share
Typical surprise -1.2% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 6$-0.84 vs $-0.84beat
- Thu, May 7$-0.83 vs $-0.82miss
- Tue, Mar 3$-0.88 vs $-0.88beat
- Fri, Nov 14$-0.90 vs $-0.84miss
- Wed, Aug 6$-0.98 vs $-0.66miss
- Wed, May 14$-0.67 vs $-0.63miss
Estimates and results for SRRK via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by SRRK officers and directors.
- Bought
- $1.2m
- Sold
- $19.4m
3 trades
38 trades
- Flier Jeffrey S.sold
- Flier Jeffrey S.sold
- Flier Jeffrey S.sold
- Gilman Michaelsold
- Gilman Michaelsold
- Gilman Michaelsold
- Burow Kristinasold
- Burow Kristinasold
59 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in SRRK.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.